Long-term outcomes for children with acute lymphoblastic leukemia (ALL) treated on The Cancer Institute of New Jersey ALL trial (CINJALL)

Leukemia & Lymphoma
Richard A DrachtmanPeter D Cole

Abstract

The Cancer Institute of New Jersey Acute Lymphoblastic Leukemia trial (CINJALL) employed a post-induction regimen centered on intensive oral antimetabolite therapy, with no intravenous methotrexate (MTX). Fifty-eight patients enrolled between 2001 and 2005. A high rate of induction death (n = 3) or induction failure (n = 1) was observed. Among those who entered remission, five-year DFS is 80 ± 8.9% for those at standard risk of relapse and 76 ± 7.8% for high-risk patients, with median follow up over six years. The estimated cumulative incidence of testicular relapse among boys was elevated (13 ± 7.2%) compared to the rate observed on contemporary protocols. We conclude that post-induction therapy using intensive oral antimetabolites for children with acute lymphoblastic leukemia (ALL) can result in overall long-term DFS comparable to that observed among children treated with regimens including intravenous MTX. However, an increased risk of late extramedullary relapse among boys was observed, supporting the prevailing opinion that high-dose MTX improves outcome for children with ALL.

References

Sep 20, 2005·Cancer Chemotherapy and Pharmacology·Peter D ColeBarton A Kamen
Nov 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter D ColeBarton A Kamen
Sep 5, 2007·Cancer Chemotherapy and Pharmacology·Peter D ColeBarton A Kamen
Dec 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suman MalempatiUNKNOWN Children's Oncology Group
Aug 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth A RaetzWilliam L Carroll
Dec 17, 2009·Leukemia·K SchmiegelowUNKNOWN Nordic Society of Paediatric Haematology and Oncology
Feb 8, 2011·Nature Genetics·Jun J YangMary V Relling
Mar 14, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen P HungerWilliam L Carroll
May 9, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Smita BhatiaF Lennie Wong
Feb 20, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deepa BhojwaniMary V Relling

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.